Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion type Assertion NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_head.
- NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion description "[Metformin has been used as first-line treatment in patients with type 2 diabetes, and is reported to reduce cancer risk and progression by activating the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_provenance.
- NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion evidence source_evidence_literature NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_provenance.
- NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion SIO_000772 23526220 NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_provenance.
- NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion wasDerivedFrom befree-20150227 NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_provenance.
- NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_assertion wasGeneratedBy ECO_0000203 NP719518.RAWaXpaL4l5cR-xrPh8LSWf6eeDhOVeYkpnoSr2OK_6Vo130_provenance.